Thus, taken together, these results suggest that mOMVs can be utilized as a safe ocular-mucosal vaccine capable of inducing a protective immune response against HUS-causative OMVs of EHEC O157 bacteria

Thus, taken together, these results suggest that mOMVs can be utilized as a safe ocular-mucosal vaccine capable of inducing a protective immune response against HUS-causative OMVs of EHEC O157 bacteria. Supporting Information Figure S1 Eyedrop vaccination of mOMVs resulted in wtOMVs cross-reactive Ab production. serum and mucosal immunoglobulins, body weight change and blood urea nitrogen (BUN)/Creatinin (Cr) were tested, as well as histopathology of renal tissue. In order to confirm the safety of mOMVs for eyedrop use, body weight and ocular CCG-1423 histopathological changes were monitored in mice. Modified OMVs having penta-acylated lipid A moiety did not contain STxA subunit proteins but retained non-toxic Shiga toxin B (STxB) subunit. Removal of the polymeric O-antigen of O157 LPS was confirmed in waaJ-mOMVs. The mice group vaccinated with mOMVs elicited greater humoral and mucosal immune responses than did the waaJ-mOMVs and PBS-treated groups. Eyedrop vaccination of mOMVs plus PMB reduced the level of humoral and mucosal immune responses, suggesting that intact O157 LPS antigen can be a crucial component for enhancing the immunogenicity of the mOMVs. After challenge, mice vaccinated with mOMVs were guarded from a lethal dose of wtOMVs administered intraperitoneally, conversely mice in the PBS control group were not. Collectively, for the first time, EHEC O157-derived mOMV eyedrop vaccine was experimentally evaluated as an efficient and safe means of vaccine development against EHEC O157:H7 infection-associated HUS. Introduction Enterohemorrhagic (EHEC) can cause severe diarrhea, hemorrhagic colitis, which is usually often accompanied by hemolytic anemia, thrombocytopenia, and acute renal failure, which are the hallmarks of hemolytic uremic syndrome (HUS) [1]. Although common CCG-1423 EHEC strains are classified by the production of Shiga toxin (STx) and the possession of a locus of enterocyte effacement (LEE) in the chromosome, atypical EHEC lacking LEE pathogenicity islands can be associated with HUS, as recently witnessed in a German outbreak of O104:H4 [2]. Despite the lethal outbreak of HUS due to O104:H4, EHEC O157:H7 remains the most important causative strain involved in the manifestation of HUS worldwide [3]. Accordingly, the development of effective vaccines preventing EHEC O157:H7 infection-associated HUS are of primary research interest. Outer membrane vesicles (OMVs) are spherical membrane blebs shed CCG-1423 by Gram-negative bacteria [4]. They carry not only CCG-1423 native antigens expressed in the outer membrane, but also exogenous protein epitopes [5] and retain self-adjuvanticity that can be exerted by the inclusion of toll-like receptor agonists (lipopolysaccharide [LPS], outer membrane lipoproteins, flagellin, etc.) [6]. Several reports have exhibited that vaccination with OMVs is sufficient to induce an immune response and safeguard vaccinated organisms from subsequent pathogen challenge [7]C[10]. However, up until now, an effective and safe OMV vaccine for protection from EHEC O157:H7 contamination and sequelae HUS has not been reported, presumably because OMVs generated from EHEC O157:H7 are intrinsically toxic due to presence of STx exotoxin and LPS endotoxin, which are two major virulence factors that contribute towards development of HUS. In order to overcome the toxicity of the EHEC O157-OMVs, we used a detoxified OMV (produced from MsbB- and STxA-deficient mutant) that was characterized previously for use as a vaccine [5], [11]. Moreover, we generated waaJ-mOMVs, which were composed of a truncated version of O157-LPS lacking the O-antigen side Rabbit Polyclonal to CHRNB1 chains, to test whether the CCG-1423 absence of O-antigen in LPS would affect immunogenicity of mOMVs administered via an ocular-mucosal route. We found that eyedrop vaccination with mOMVs of EHEC O157:H7 induced humoral and mucosal immune responses and, without the use of commercial adjuvants, was able to safeguard immunized mice from further challenge with wtOMVs, which are believed to be produced in the gut of EHEC O157-infected hosts and have been suggested as the causative agent for HUS [12]. We also exhibited that loss of the O-antigen by truncation of O157-LPS to the core region made waaJ-mOMVs significantly less immunogenic, indicating the LPS O-antigen in the mOMVs plays a significant role in inducing a protective immune response against lethal O157-OMV challenge..